Key milestones of RNA development

1961

Discovery of mRNA and its function

1969

In vitro translation of isolated mRNA in a cell-free system

1978

Development of liposome–mRNA formulations

1989

Development of cationic LNP–mRNA formulations

1990

Free mRNA translation post intramuscular injection in mice

1992

Injection of vasopressin mRNA into rat brain as protein replacement therapy for diabetes insipidus

1993

Development of liposome–mRNA formulations as influenza vaccine

1995

Injection of carcinoembryonic antigen mRNA into mouse muscle as a cancer vaccine

2001

First clinical trial of mRNA-engineered dendritic cells (NCT00004211)

2005

Nucleoside-modified mRNA shows reduced immunogenicity

2009

Clinical trial of mRNA therapeutics using protamine–mRNA formulations (NCT00204607)

2014

Clinical trial of LNP–mRNA formulations for cancer immunotherapies (NCT02316457)

2015

SyVento BioTech is founded with a commitment to develop lipid-based drug delivery systems. Leveraging their experience and expertise, the company focuses on creating innovative and effective lipid nanoparticle solutions for RNA-based medicine

2017

• Clinical trial of LNP–mRNA formulations as influenza vaccines (NCT03076385)
• Clinical trial of LNP–mRNA formulationsfor protein replacement therapies (NCT03375047)
• First in-human test of personalized mRNA cancer vaccines

2020

• mRNA-1273 and BNT162b (LNP–mRNA formulations) COVID-19 mRNA vaccines obtained authorization from regulatory agencies in multiple countries
• Clinical trial of LNP formulations delivering gene-editing components for genetic disorders (NCT04601051)

2021

SyVento and OncoArendi (currently Molecure) sign a joint development collaboration and exclusive global licensing agreement for the use of the nanoliposomal formulation of the arginase inhibitor OATD-02, further solidifying SyVento's reputation in the field

2023

SyVento BioTech opens its state-of-the-art R&D facility, expanding its research capabilities in lipid-based drug delivery systems and RNA-based medicine. This advanced research and production facility distinguishes the company as a standout in this part of the world, reflecting its commitment to innovation and excellence

Xucheng Hou, Tal Zaks, Robert Langer, Yizhou Dong. ” Lipid nanoparticles for mRNA delivery.” Nature Reviews Materials volume 6, (2021): pages1078–1094. https://doi.org/10.1038/s41578-021-00358-0

This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.